Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation

Table 1 Group1: Demonstration of demographic characteristics, structural and functional changes of group1 to which WJ-MSC and rEMS combination was applied

Patient no	Eye	Toxin	BCVA		Visual field FPDI		GCC thickness		VEP P100 lat.VEP P100 lat		VEP P100 ampl
Patient no	Eye	Toxin	Before	After	Before	After	Before	After	Before	After	Before	After
1	L	Methanol	80	98	49	69	101	82	132	105	3.1	5.8
2	R	Methanol	35	92	15	72	92	64	148	112	2.1	4.7
3	L	Amiodarn	89	110	34	98	103	88	136	101	3.4	7.2
4	L	Methanol	35	80	47	65	88	61	154	114	1.1	4.2
5	R	Sildenafil	50	83	38	61	94	60	144	114	1.8	3.4
6	L	Methanol	50	98	37	59	91	70	139	106	2.9	6.3
7	L	C0₂	39	65	11	28	71	52	140	118	3.6	7.1
8	R	Methanol	35	45	7	14	62	50	149	131	2.7	3.9
9	R	Methanol	40	50	5	11	64	51	157	136	1.4	2.6
10	R	Methanol	54	54	8	10	62	58	147	128	1.6	2.9
11	L	Methanol	35	40	4	11	58	56	145	130	1.0	2.6
12	R	Methanol	35	35	1	2	55	50	153	132	1.2	2.3

WJ-MSC Wharton’s jelly derived mesenchymal stem cell, rEMS repetitive electromagnetic stimulation, BCVA best corrected visual acuity (ETDRS letters), FPDI fundus perimetry deviation index (%), GCC thickness Ganglion cell complex (µm), VEP visual evoked potential, P100 lat latency (ms), P100 ampl amplitude (mV)

ISSN: 1757-6512